 |
BioWorld-International-2006-04-05
$53M Added To Chromatin For CHR-2797 Phase II Trial
$53M Added To Chromatin For CHR-2797 Phase II Trial
LONDON - Chromatin biology specialist Chroma Therapeutics raised £53 million in a third-round funding, enabling it to move the lead program CHR-2797 through Phase II studies and get two other compounds into the clinic. (BioWorld International)